Altekruse SF, Kosary CL, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
American Cancer Society. Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society; 2012.
American Joint Committee on Cancer. Stomach Cancer. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 117–121.
Bae J, Lee E, Guyatt G. Citrus fruit intake and stomach cancer risk: a quantitative systematic review. Gastric Cancer. 2008;11:23–-32.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19.
Bendell J. Latest data on the treatment of upper gastrointestinal cancers. ASCO Education Book 2008:184−190.
Brooks-Wilson, P. Kaurah and G. Suriano et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer assessment of 42 new families and review of genetic screening criteria. Journal of Medical Genetics 2004;41:508–517.
Capelle LG, de Vries AC, Looman CW, Casparie MK, Boot H, Meijer GA, Kuipers EJ. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008 Nov;44(16):2470–2476.
Cunningham D, Allum W, Stenning S et al. Perioperative chemotherapy vs surgery alone for resectable gastroesophageal cancer. N Eng J Med. 2006;355:11–20.
Dhalla F, da Silva SP, Lucas M, Travis S, Chapel H. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin Exp Immunol. 2011 Jul;165(1):1−7.
Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–397.
Gunderson LL, Donohue JH, Alberts SR. Cancer of the Stomach. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1431–1464.
Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305–315.
Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975−2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric cancer patients treated with gastrectomy. Cancer. 2000;88:921–932.
Hwang J. Resectable esophageal, gastroesophageal and gastric cancers: therapy is distinct for gastric cancer. ASCO Education Book 2008:172–176.
Jeung H, Moon Y, Rha S, et al. Phase III trial of adjuvant 5-flourouracil and adriamycin versus 5-flourouracil and adriamycin and polyadenylic-polyuridylic acid (poly a:u) for locally advanced gastric cancer after curative surgery: final results of 15 year follow-up. Annals of Oncology. 2008;19:520–526.
Kang Y, Chang H, Zang D et al. Postoperative adjuvant chemotherapy for grossly serosa positive advanced gastric cancer: a randomized phase III trial of intraperitoneal cisplatin and early mitomycin C plus long term doxifluridine plus cisplatin versus mitomycin-C plus short-term doxifluridine. J Clin Oncol. 2008;26 (May 20 suppl; abstr LBA4511).
Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9:828–830.
Koizumi W, Akiya T, HaraT et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221.
Liu JF, Jamieson GG, Wu TC, Zhu GJ, Drew PA. A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol. 2009 5:1397–1402.
MacDonald JS, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med. 2001;345:725–730.
Mansfield P, Yao JC, Crane CH. Gastric Cancer. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine. 6th ed. Hamilton, Ontario: BC Decker; 2003:1515–1542.
Märkl B, Moldovan AI, Jähnig H, Cacchi C, Spatz H, Anthuber M, Oruzio DV, Kretsinger H, Arnholdt HM. Combination of ex vivo sentinel lymph node mapping and methylene blue-assisted lymph node dissection in gastric cancer: a prospective and randomized study. Ann Surg Oncol. 2011 Jul;18(7):1860−1868.
Muro K, Boku N, Yamada Y et al. Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer: preliminary results. J Clin Oncol. 2008;26 (May 20 suppl; abstr 4541).
National Cancer Institute. Physician Data Query (PDQ). Gastric Cancer: Treatment. 10/14/2011. Accessed at: www.cancer.gov/cancertopics/pdq/treatment/gastric/HealthProfessional on November 14, 2011.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. v.2.2011. Accessed at www.nccn.org on November 10, 2011.
Pisters PWT, Kelsen DP, Powell SM, Tepper JE. Cancer of the stomach, In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008:1043–1079.
Pozzo C and Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist. 2008;13:794–806.
Sousa H, Pinto-Correia AL, Medeiros R, Dinis-Ribeiro M. Epstein-Barr virus is associated with gastric carcinoma: the question is what is the significance? World J Gastroenterol. 2008;14(27):4347–4351.
Feedback
